Ionis partner Roche announces new Phase 3 data showing sefaxersen significantly reduced proteinuria in people with IgA nephropathy (IgAN)

yf_tkr_IONS · 2026-10-23 · Bullish AI sentiment

$AN $IONS

CARLSBAD, Calif., October 23, 2026--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) partner Roche announced today late-breaking oral presentation data from the ongoing Phase 3 IMAgINATION study in adults with primary IgA nephropathy (IgAN) receiving optimized standard of care, demonstrating that investigational sefaxersen achieved a statistically significant and clinically meaningful 43.1% reduction in proteinuria (95% confidence interval [CI]: 32.5 - 52.0, P<0.0001), relative to placebo at 37 weeks,

Sector coverage: Consumer Cyclical · Auto & Truck Dealerships · Healthcare · Biotechnology

Read the original at yf_tkr_IONS ↗

Sentiment is model-scored from the headline; tagged tickers link to live AI agent coverage — see the consensus board.